La bourse est fermée

Catalent, Inc. (CTLT)

NYSE - Nasdaq Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
56,45-0,03 (-0,05 %)
À la clôture : 04:00PM EDT
56,50 +0,05 (+0,09 %)
Échanges après Bourse : 06:21PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - Specialty & Generic
Employés à temps plein18 000

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Alessandro MaselliPresident, CEO & Director1,08MS.O.1972
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment799,26kS.O.1966
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff622,12kS.O.1977
Mr. John J. Greisch M.B.A.Executive Chairman of the Board125kS.O.1955
Mr. Matti M. MasanovichSenior VP & CFOS.O.S.O.1972
Mr. Michael J. Hatzfeld Jr.VP & Chief Accounting OfficerS.O.S.O.1974
Mr. Charles LickfoldSenior VP & Chief Information OfficerS.O.S.O.1974
Mr. Paul SurdezVice President of Investor RelationsS.O.S.O.S.O.
Mr. Joseph A. Ferraro J.D.Senior VP, General Counsel, Chief Compliance Officer & SecretaryS.O.S.O.1979
Mr. Michael J. GrippoSenior Vice President of Strategy & Corporate DevelopmentS.O.S.O.1969
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Catalent, Inc. en date du 1 mars 2024 est 10. Les scores principaux sont Audit : 10; Société : 8; Droits des actionnaires : 7; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.